Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma

PLoS One. 2013;8(3):e58913. doi: 10.1371/journal.pone.0058913. Epub 2013 Mar 18.

Abstract

Background: Interferon (IFN)-α is effective in inhibiting tumor growth and metastasis of hepatocellular carcinoma (HCC). However, the biologic mechanisms of IFN-α treatment in lung metastasis are not yet clear.

Methods: The effect of IFN-α treatment was studied by using an orthotopic xenograft model and measuring tumor size and lung metastasis. Pretreatment with IFN-α before implantation of tumor was done to explore the effect of IFN-α on lung tissues. Cytokines and macrophages were measured by immunohistochemistry and/or PCR assay, using human origin or mouse origin primers to differentiate the sources. Circulating tumor cells (CTCs) were also assayed by flow cytometry.

Results: IFN-α treatment did not decrease the number of CTCs (0.075% ± 0.020% versus 0.063%±0.018%, P = 0.574, IFN-α-treated versus control groups), but did decrease the number and size of lung metastasis (number: 1.75 ± 1.0 versus 28.0 ± 6.3, P = 0.008; size [pixels]: 116.8 ± 72.2 versus 5226.4 ± 1355.7, P = 0.020), and inhibited macrophage infiltration (0.20% ± 0.04% versus 1.36% ± 0.21%, P = 0.0058) and alteration of matrix metalloproteinase (MMP)-9 expression (mean integrated optical density (IOD): 5.1 ± 1.7 versus 21.9 ± 0.4, P<0.000) in the lung, which was independent of the primary tumor.

Conclusion: IFN-α inhibited lung metastasis by directly modulating the lung microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / pathology*
  • Cell Line, Tumor
  • Cellular Microenvironment / drug effects*
  • Disease Models, Animal
  • Humans
  • Interferon-alpha / pharmacology*
  • Interferon-alpha / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary*
  • Macrophages / drug effects
  • Macrophages / pathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Neoplastic Cells, Circulating / drug effects
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / genetics
  • Neovascularization, Pathologic / metabolism
  • Tumor Burden / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Interferon-alpha
  • Matrix Metalloproteinase 9

Grants and funding

Grant support, National Natural Science Foundation of China (No.81101851). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.